ECSP21003520A - Inhibidores de proteína tirosina fosfatasa y sus métodos de uso - Google Patents

Inhibidores de proteína tirosina fosfatasa y sus métodos de uso

Info

Publication number
ECSP21003520A
ECSP21003520A ECSENADI20213520A ECDI202103520A ECSP21003520A EC SP21003520 A ECSP21003520 A EC SP21003520A EC SENADI20213520 A ECSENADI20213520 A EC SENADI20213520A EC DI202103520 A ECDI202103520 A EC DI202103520A EC SP21003520 A ECSP21003520 A EC SP21003520A
Authority
EC
Ecuador
Prior art keywords
protein tyrosine
tyrosine phosphatase
methods
phosphatase inhibitors
ptpn1
Prior art date
Application number
ECSENADI20213520A
Other languages
English (en)
Inventor
Hongyu Zhao
Phil Kym
Jennifer Frost
Christina Baumgartner
Elliot Farney
Roohollah Shiroodi
Geoff Halvorsen
Jason Abbott
Christos Economou
Matthew O'connor
Zhaoming Xiong
Xueqing Wang
Andrew Bogdan
Qingwei Zhang
Original Assignee
Calico Life Sciences Llc
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc, Abbvie Inc filed Critical Calico Life Sciences Llc
Publication of ECSP21003520A publication Critical patent/ECSP21003520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones y métodos útiles para inhibir proteína tirosina fosfatasa, por ejemplo, proteína tirosina fosfatasa no receptora de tipo 2 (PTPN2) y/o proteína tirosina fosfatasa no receptora de tipo 1 (PTPN1) y para tratar enfermedades, trastornos y condiciones relacionadas que responden favorablemente al tratamiento con inhibidor de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
ECSENADI20213520A 2018-06-21 2021-01-18 Inhibidores de proteína tirosina fosfatasa y sus métodos de uso ECSP21003520A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862688226P 2018-06-21 2018-06-21

Publications (1)

Publication Number Publication Date
ECSP21003520A true ECSP21003520A (es) 2021-02-26

Family

ID=67254011

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20213520A ECSP21003520A (es) 2018-06-21 2021-01-18 Inhibidores de proteína tirosina fosfatasa y sus métodos de uso

Country Status (23)

Country Link
US (1) US10954202B2 (es)
EP (1) EP3810580A1 (es)
JP (2) JP7217762B2 (es)
KR (2) KR102533477B1 (es)
CN (1) CN112955438A (es)
AR (1) AR125425A1 (es)
AU (2) AU2019290197B2 (es)
BR (1) BR112020026086A2 (es)
CA (1) CA3104507A1 (es)
CL (1) CL2020003316A1 (es)
CO (1) CO2021000447A2 (es)
CR (1) CR20210017A (es)
DO (1) DOP2020000252A (es)
EC (1) ECSP21003520A (es)
IL (1) IL279587A (es)
MA (1) MA52963A (es)
MX (2) MX2020014223A (es)
PE (1) PE20210372A1 (es)
PH (1) PH12020552228A1 (es)
SG (1) SG11202012820PA (es)
TW (1) TW202016082A (es)
UY (1) UY38272A (es)
WO (1) WO2019246513A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP7204005B2 (ja) * 2019-03-14 2023-01-13 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
WO2021108867A1 (en) * 2019-12-04 2021-06-10 Monash University Methods of activating cytotoxic leukocytes using ptp1b and ptpn2 inhibitors
CA3162069A1 (en) * 2019-12-18 2021-06-24 Elliot P. Farney Protein tyrosine phosphatase inhibitors and methods of use thereof
CA3223322A1 (en) * 2021-06-21 2022-12-29 Gesine Kerstin Veits Degrader compounds and uses thereof
CA3236854A1 (en) * 2021-11-11 2023-05-19 Andrew Bogdan Protein tyrosine phosphatase inhibitors and methods of use thereof
CN118556055A (zh) * 2021-11-11 2024-08-27 卡里科生命科学有限责任公司 蛋白酪氨酸磷酸酶抑制剂及其使用方法
CN115197167B (zh) * 2022-07-22 2023-07-28 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024102791A1 (en) * 2022-11-09 2024-05-16 Bristol-Myers Squibb Company Indazol substituted 1,2,5-thiadiazolidin derivatives as inhibitors of protein tyrosine phosphatase (ptpn2) for the treatment of cancer diseases
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO2003037328A1 (en) 2001-10-30 2003-05-08 Applied Research Systems Ars Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
BR0308974A (pt) * 2002-04-03 2005-02-15 Novartis Ag Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
US20100160228A1 (en) 2007-05-23 2010-06-24 Valtion Teknillinen Tutkimuskeskus Method for inhibiting or stimulating angiogenesis in an individual
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
WO2010118241A2 (en) 2009-04-08 2010-10-14 Indiana University Research & Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
US20130202577A1 (en) 2010-02-03 2013-08-08 Monash University Diagnostic and prognostic assay for breast cancer
WO2015127548A1 (en) 2014-02-28 2015-09-03 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
US20170224731A1 (en) 2014-06-10 2017-08-10 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
US20180325925A1 (en) 2015-11-06 2018-11-15 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
WO2018227248A1 (en) 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity
US11597739B2 (en) 2017-08-24 2023-03-07 The Royal Institution For The Advancement Of Learning/Mcgill University Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP)

Also Published As

Publication number Publication date
KR102533477B1 (ko) 2023-05-18
JP2021530443A (ja) 2021-11-11
PH12020552228A1 (en) 2021-08-16
US20210009542A1 (en) 2021-01-14
CO2021000447A2 (es) 2021-07-19
BR112020026086A2 (pt) 2021-03-23
CR20210017A (es) 2021-11-03
TW202016082A (zh) 2020-05-01
PE20210372A1 (es) 2021-02-26
AU2023263567A1 (en) 2023-11-30
JP2023055771A (ja) 2023-04-18
SG11202012820PA (en) 2021-01-28
KR20230074286A (ko) 2023-05-26
MA52963A (fr) 2021-04-28
JP7217762B2 (ja) 2023-02-03
EP3810580A1 (en) 2021-04-28
CA3104507A1 (en) 2019-12-26
CN112955438A (zh) 2021-06-11
MX2020014223A (es) 2021-06-23
CL2020003316A1 (es) 2021-06-11
WO2019246513A1 (en) 2019-12-26
AU2019290197A1 (en) 2021-01-21
KR20210034589A (ko) 2021-03-30
AR125425A1 (es) 2023-07-19
AU2019290197B2 (en) 2023-08-24
UY38272A (es) 2019-12-31
DOP2020000252A (es) 2021-07-15
IL279587A (en) 2021-03-01
MX2024004318A (es) 2024-04-23
US10954202B2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
UY38613A (es) Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
MX2020004534A (es) Moduladores de la vía integrada del estrés.
EA201691135A1 (ru) Новые ингибиторы глутаминазы
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
NI202000085A (es) Moduladores de la expresión de apol1
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112022010672A2 (pt) Agentes ativos acilados e métodos de seu uso para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica
ECSP21042779A (es) Moduladores de la expresión de irf5
EA201991267A1 (ru) Ингибиторы мутантных изоцитратдегидрогеназ и их композиции и способы